home / stock / cybn:cc / cybn:cc quote
Last: | $0.67 |
---|---|
Change Percent: | -1.47% |
Open: | $0.67 |
Close: | $0.67 |
High: | $0.68 |
Low: | $0.64 |
Volume: | 67,599 |
Last Trade Date Time: | 05/06/2022 04:52:03 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.67 | $0.67 | $0.67 | $0.68 | $0.64 | 67,599 | 05-06-2022 |
$0.68 | $0.7 | $0.68 | $0.71 | $0.66 | 91,840 | 05-05-2022 |
$0.69 | $0.72 | $0.69 | $0.73 | $0.67 | 164,216 | 05-04-2022 |
$0.74 | $0.73 | $0.74 | $0.78 | $0.71 | 189,598 | 05-03-2022 |
$0.73 | $0.78 | $0.73 | $0.78 | $0.71 | 112,343 | 05-02-2022 |
$0.74 | $0.7 | $0.74 | $0.77 | $0.68 | 138,481 | 04-29-2022 |
$0.7 | $0.81 | $0.7 | $0.81 | $0.58 | 412,631 | 04-28-2022 |
$0.81 | $1 | $0.81 | $1 | $0.79 | 165,245 | 04-27-2022 |
$0.81 | $0.92 | $0.81 | $0.92 | $0.71 | 179,616 | 04-26-2022 |
$0.91 | $0.94 | $0.91 | $0.94 | $0.89 | 63,955 | 04-25-2022 |
$0.92 | $0.95 | $0.92 | $0.96 | $0.91 | 34,214 | 04-22-2022 |
$0.92 | $0.94 | $0.92 | $0.95 | $0.91 | 61,240 | 04-21-2022 |
$0.93 | $0.99 | $0.93 | $0.99 | $0.93 | 39,175 | 04-20-2022 |
$0.97 | $1.03 | $0.97 | $1.03 | $0.97 | 264,811 | 04-19-2022 |
$0.98 | $1.03 | $0.98 | $1.03 | $0.96 | 102,501 | 04-18-2022 |
$1.02 | $1.01 | $1.02 | $1.02 | $0.97 | 124,293 | 04-15-2022 |
$1.02 | $1.01 | $1.02 | $1.02 | $0.97 | 118,548 | 04-14-2022 |
$1 | $0.92 | $1 | $1.01 | $0.9 | 154,099 | 04-13-2022 |
$0.93 | $0.92 | $0.93 | $0.94 | $0.9 | 54,391 | 04-12-2022 |
$0.92 | $0.96 | $0.92 | $0.96 | $0.9 | 183,542 | 04-11-2022 |
News, Short Squeeze, Breakout and More Instantly...
CYBIN INC. Company Name:
CYBN:CC Stock Symbol:
AQNC Market:
Cybin (NYSE American: CYBN) (Cboe CA: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options. The company has provided a corporate update highlighting recent clinical ...
- Recent U.S. $150 Million funding round lead by a syndicate of leading biopharmaceutical institutional investors supports advancement of clinical-stage programs CYB003 and CYB004 - - Received U.S. Food and Drug Administration (“FDA”) Breakthrough Therapy Designation (ȁ...
Cybin (NYSE American: CYBN) (Cboe CA: CYBN) , a clinical-stage biopharmaceutical company developing new and innovative next-generation psychedelic-based treatment options, is announcing its participation at the 27th Annual Milken Institute Global Conference, set to take place May 5-8, 2024, at th...